In osteosarcoma, both in vivo and in vitro experiments indicate that the lncRNA SOX2OT variant seven can activate DLL3/Notch3 signaling, maintaining the stemness and doxorubicin-resistance of tumor cells (Wang et al., 2018b). This evidence concerns the gene DLL3 and osteosarcoma.